REDWOOD CITY, Calif.,
Jan. 11, 2016 /PRNewswire/
-- Genomic Health, Inc. (Nasdaq: GHDX) today announced plans
to launch its first liquid biopsy test, Oncotype SEQ™, in mid-2016.
The test is a blood-based mutation panel that uses next-generation
sequencing to identify select actionable genomic alterations for
the treatment of patients with late-stage lung, breast, colon,
melanoma, ovarian or gastrointestinal cancer. As a fit-for-purpose
panel, Oncotype SEQ is designed to meet the needs of community
oncologists by delivering actionable clinical information to the
more than 350,000 cancer patients who recur or present with
late-stage disease each year in the
United States alone.
"Non-invasive liquid biopsy tests offer a significant
opportunity to transform the management of cancer, and it is our
goal to deliver multiple products across oncology and urology
beginning with Oncotype SEQ," said Phil
Febbo, M.D., chief medical officer of Genomic Health. "We
believe we are well positioned to lead this new market given our
experience developing cancer tests that are optimized for clinical
utility and patient access, along with our operational expertise
and unmatched commercial channel."
Oncotype SEQ represents the first of several liquid biopsy tests
that Genomic Health plans to deliver through the introduction of
its Oncotype IQ™ Genomic Intelligence Platform. This portfolio
of genomic tests and services currently consists of the Company's
flagship line of Oncotype DX gene expression tests that have been
used to guide treatment decisions for more than 600,000 cancer
patients worldwide. In the future, Genomic Health plans to
expand its test portfolio through both internal product development
and partnerships to include additional tissue and liquid-based
tests for the management and monitoring of multiple cancer
types.
About Genomic Health
Genomic Health, Inc. (NASDAQ: GHDX) is the world's leading provider
of genomic-based diagnostic tests that address both the
overtreatment and optimal treatment of early-stage cancer, one of
the greatest issues in healthcare today. The company is applying
its world-class scientific and commercial expertise and
infrastructure to lead the translation of massive amounts of
genomic data into clinically-actionable results for treatment
planning throughout the cancer patient's journey, from diagnosis to
treatment selection and monitoring. The company is based
in Redwood City, California, with international
headquarters in Geneva, Switzerland. For more
information, please visit, www.GenomicHealth.com and
follow the company on
Twitter: @GenomicHealth, Facebook, YouTube and LinkedIn.
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including the timing of the planned launch of Oncotype SEQ
and the expected attributes and benefits of the panel; the
company's belief that it is well-positioned to lead the new liquid
biopsy market; and the company's plans to deliver additional tests
through its IQ Genomic Intelligence Platform. Forward-looking
statements are subject to risks and uncertainties that could cause
actual results to differ materially, and reported results should
not be considered as an indication of future performance. These
risks and uncertainties include, but are not limited to: the
completion of the company's quarter and year-end close processes,
and adjustments that may result from such processes; the impact of
ERP implementation on the company's business; the risks and
uncertainties associated with the regulation of the company's
tests; the results and timing of results of clinical studies and
their impact on reimbursement and adoption; the applicability of
clinical study results to actual outcomes; the company's ability to
develop and commercialize new tests, including Oncotype SEQ, and
expand into new markets domestically and internationally; the risk
that the company may not obtain, within its time expectations or at
all, or maintain sufficient levels of reimbursement, domestically
or abroad, for its existing tests and any future tests it may
develop; the risks of competition; unanticipated costs or delays in
research and development efforts; and the other risks set forth in
the company's filings with the Securities and Exchange Commission,
including the risks set forth in the company's quarterly report on
Form 10-Q for the quarter ended September
30, 2015. These forward-looking statements speak only as of
the date hereof. Genomic Health disclaims any obligation to update
these forward-looking statements.
NOTE: The Genomic Health logo, Oncotype,
Oncotype DX, Recurrence Score, and DCIS Score are trademarks or
registered trademarks of Genomic Health, Inc. All other
trademarks and service marks are the property of their respective
owners.
Logo -
http://photos.prnewswire.com/prnh/20130425/SF01493LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/genomic-health-announces-plans-to-launch-liquid-biopsy-mutation-panel-in-2016-300201884.html
SOURCE Genomic Health, Inc.